Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-1,41%
1 076,13
-15,38
-1,41%
—1 091,511 090,401 090,401 073,69——
SIXC
Communications
SIXC
Communications
SIXC
-0,55%
606,74
-3,37
-0,55%
—610,11610,11610,29606,17——
SIXE
Energy
SIXE
Energy
SIXE
+0,88%
1 248,82
+10,84
+0,88%
—1 237,981 237,831 252,411 225,03——
SIXI
Industrials
SIXI
Industrials
SIXI
-1,17%
1 724,36
-20,35
-1,17%
—1 744,711 740,951 747,291 721,57——
SIXM
Financials
SIXM
Financials
SIXM
-0,72%
635,59
-4,59
-0,72%
—640,18639,92643,19634,73——
SIXR
Staples
SIXR
Staples
SIXR
-0,76%
843,15
-6,43
-0,76%
—849,58845,27851,68839,47——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,55%
216,29
-1,19
-0,55%
—217,48217,48218,16215,51——
SIXT
Technology
SIXT
Technology
SIXT
+0,08%
3 263,41
+2,72
+0,08%
—3 260,693 273,363 287,813 240,78——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,34%
939,24
-3,21
-0,34%
—942,45939,39948,80933,98——
SIXV
Health care
SIXV
Health care
SIXV
-0,29%
1 462,56
-4,24
-0,29%
—1 466,801 464,701 467,191 458,36——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,71%
2 380,40
-17,10
-0,71%
—2 397,502 395,032 412,012 370,64——
GSK:NYSE
GSK plc
50,90 US$
-1,38%
(-0,71) 1D
50,99 US$
+0,18% (+0,090)
After hours
Closed: 4 მაი, 16:00:02 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GSK...
Open
51,52 US$
High
51,61 US$
Low
50,78 US$
Mkt. cap
102,51 მლრ.
Avg. vol.
4,41 მლნ.
Volume
3,20 მლნ.
Dividend
3,49%
Quarterly dividend
0,44 US$
Ex dividend date
14 მაი. 2026
P/E ratio
13,17
52-wk high
61,70 US$
52-wk low
35,45 US$
EPS
3,87 US$
Beta
0,29
Shares outstanding
2,03 მლრდ.
No. of employees
67 ათ.
News stories
From sources across the web
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK. The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOემა უოლმსლი | ემა უოლმსლი
Employees66,8 ათ.
Founded27 დეკ. 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com
Last report
29 აპრ. 2026
Fiscal Period
Q1 2026
Normalized EPS / Estimate
46,50/ (0,44 est.)GBP
+10 388,80%beat
Revenue / Estimate
7,63 მლრდ./ (7,61 მლრდ. est.)GBP
+0,22%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in GBP
ივნ. 2025
სექ. 2025
დეკ. 2025
მარ. 2026
Revenue
7,99 მლრდ.
8,55 მლრდ.
8,62 მლრდ.
7,63 მლრდ.
Cost of goods sold
2,16 მლრდ.
2,24 მლრდ.
2,62 მლრდ.
1,87 მლრდ.
Cost of revenue
2,16 მლრდ.
2,24 მლრდ.
2,62 მლრდ.
1,87 მლრდ.
Research and development expenses
1,54 მლრდ.
1,58 მლრდ.
2,14 მლრდ.
1,52 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,13 მლრდ.
2,16 მლრდ.
2,67 მლრდ.
2,08 მლრდ.
Operating expense
3,43 მლრდ.
3,23 მლრდ.
4,37 მლრდ.
2,99 მლრდ.
Total operating expenses
5,59 მლრდ.
5,46 მლრდ.
6,99 მლრდ.
4,86 მლრდ.
Operating income
2,39 მლრდ.
3,08 მლრდ.
1,63 მლრდ.
2,77 მლრდ.
Other non operating income
-
-
-21,00 მლნ.
-
EBT including unusual items
1,89 მლრდ.
2,46 მლრდ.
950,00 მლნ.
2,14 მლრდ.
EBT excluding unusual items
2,26 მლრდ.
2,94 მლრდ.
1,48 მლრდ.
2,62 მლრდ.
Income tax expense
241,00 მლნ.
312,00 მლნ.
223,00 მლნ.
305,00 მლნ.
Effective tax rate
12,77%
12,70%
23,47%
14,23%
Other operating expenses
-246,00 მლნ.
-511,00 მლნ.
-434,00 მლნ.
-615,00 მლნ.
Net income
1,44 მლრდ.
2,01 მლრდ.
636,00 მლნ.
1,74 მლრდ.
Net profit margin
18,07%
23,55%
7,38%
22,77%
Earnings per share
0,46
0,55
-
-
Interest and investment income
50,00 მლნ.
26,00 მლნ.
17,00 მლნ.
22,00 მლნ.
Interest expense
-184,00 მლნ.
-167,00 მლნ.
-145,00 მლნ.
-167,00 მლნ.
Net interest expenses
-134,00 მლნ.
-141,00 მლნ.
-128,00 მლნ.
-145,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
3,55 მლრდ.
3,82 მლრდ.
2,69 მლრდ.
3,23 მლრდ.
Gain or loss from assets sale
-
-
-40,00 მლნ.
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer